Atorvastatin for the Treatment of Plaque-type Psoriasis

Toktam Faghihi, Mania Radfar, Zohre Mehrabian, Amir Hoshang Ehsani, and Mohsen Rezaei Hemami,

Disclosures

Pharmacotherapy. 2011;31(11):1045-1050. 

In This Article

Results

Forty-two patients complied with the study criteria and entered the study. One participant in the placebo group withdrew consent, and one participant in the atorvastatin group discontinued the trial due to development of somnolence. Therefore, 40 patients completed the study, with 20 patients assigned to each treatment group. Baseline demographic and clinical characteristics of participants are outlined in Table 1. No statistically significant differences between treatment groups at baseline were noted in terms of demographics and measures of disease severity (PASI score and BSA percentage).

At the end of the study, 7 patients (35%) in the atorvastatin group were also using fluocinolone acetonide, 8 (40%) fluocinolone acetonide plus salicylic acid in petroleum, 3 (15%) fluocinolone acetonide plus emollients, and 2 (10%) fluocinolone acetonide plus salicylic acid in petroleum and emollients. Similarly, in the placebo group, 3 patients (15%) were also using fluocinolone acetonide, 9 (45%) fluocinolone acetonide plus salicylic acid in petroleum, 5 (25%) fluocinolone acetonide plus emollients, 1 (5%) salicylic acid in petroleum, and 2 (10%) fluocinolone acetonide plus salicylic acid in petroleum and emollients.

Psoriasis Improvement

After 12 weeks, mean BSA percentages and PASI scores decreased significantly from baseline in both groups. However, comparison across both groups showed that the reductions in mean BSA percentages and PASI scores were not different in the atorvastatin group compared with the placebo group (Table 2).

At 12 weeks, PASI 75 was achieved in 7 patients (35%) in the placebo group and in 8 patients (40%) in the atorvastatin group, but the difference was not statistically significant (p=0.204, χ2=1.558).

Timing of Response

Clinical improvement, defined as patients' self-report of improvement as well as a decrease in pruritus, erythema, scaling, and induration, was observed by week 4.55 ± 2.84 (mean ± SD) in the atorvastatin group and by week 4.35 ± 2.5 in the placebo group.

Adverse Effects

Despite the one participant who discontinued the trial because of development of somnolence, atorvastatin was generally well tolerated. There were no complaints or clinical observation of adverse effects among those completing the study.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....